Variability in azithromycin practices among lung transplant providers in the International Society for Heart and Lung Transplantation Community.

Variability in azithromycin practices among lung transplant providers in the International Society for Heart and Lung Transplantation Community.
复制标题

DOI:
10.1016/j.healun.2021.10.008
复制
发表时间:
2022-01
期刊:
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
影响因子:
--
通讯作者:
Ramos KJ
Ramos KJ
中科院分区:
其他
文献类型:
--
作者:
Kapnadak SG;Morrell ED;Wai TH;Goss CH;Shah PD;Merlo CA;Hachem RR;Ramos KJ

文献摘要

参考文献

相似文献

慢性肺移植物功能障碍(CLAD)是肺移植(LTx)后最重要的长期并发症,临床经验表明其管理存在显著差异。我们试图捕捉国际LTx供应商中的阿奇霉素实践。通过国际心肺移植学会分发了一份调查,由103名受访者(15个国家)完成。阿奇霉素的适应症、给药时间和剂量差异很大,37例(36%)报告了不一致性,即使在其中心内也是如此。30例(29%)报告开始阿奇霉素治疗(在首次移植住院期间)。在其他73例患者中,只有10例(14%)报告等待CLAD诊断(持续≥20%肺功能下降)。大多数在CLAD风险因素/事件后开始使用阿奇霉素,包括59例(81%)FEV 1持续降低≥10%,32例(44%)淋巴细胞性细支气管炎,27例(37%)支气管肺泡灌洗嗜酸性粒细胞增多症。阿奇霉素的处方模式似乎差异很大,需要进一步的研究来阐明LTx后开始使用阿奇霉素的最佳时机和适应症。
Chronic lung allograft dysfunction (CLAD) is the most important long-term complication after lung transplant (LTx), and clinical experience suggests significant variability in its management. We sought to capture azithromycin practices among LTx providers internationally. A survey was distributed via the International Society for Heart and Lung Transplantation and completed by 103 respondents (15 countries). Azithromycin indications, timing, and dosing varied significantly, and 37 (36%) reported inconsistency even within their center. Thirty (29%) reported initiating azithromycin prophylactically (during initial transplant hospitalization). Of 73 others, only 10 (14%) reported waiting until CLAD diagnosis (with persistent ≥20% pulmonary function decline). Most initiated azithromycin after a CLAD risk-factor/event, including 59 (81%) for a persistent ≥10% decrement in FEV1, 32 (44%) for lymphocytic bronchiolitis, and 27 (37%) for bronchoalveolar lavage neutrophilia. Azithromycin prescribing patterns appear to vary significantly, and further study is needed to elucidate the optimal timing and indications for its initiation after LTx.
DOI: 10.1136/thoraxjnl-2014-205998
发表时间: 2015-05
期刊: Thorax
影响因子: 10
作者:
Corris PA;Ryan VA;Small T;Lordan J;Fisher AJ;Meachery G;Johnson G;Ward C
通讯作者: Ward C
DOI: 10.1111/ajt.13417
发表时间: 2016-01-01
影响因子: 8.8
作者:
Ruttens, D.;Verleden, S. E.;Vos, R.
通讯作者: Vos, R.
DOI: 10.1164/rccm.200601-071oc
发表时间: 2006-09-01
影响因子: 24.7
作者:
Verleden, Geert M.;Vanaudenaerde, Bart M.;Van Raemdonck, Dirk E.
通讯作者: Van Raemdonck, Dirk E.
DOI: 10.1097/01.tp.0000295981.84633.bc
发表时间: 2008-01-15
期刊: TRANSPLANTATION
影响因子: 6.2
作者:
Gottlieb, Jens;Szangolies, Jennifer;Welte, Tobias
通讯作者: Welte, Tobias
DOI: 10.1016/j.healun.2019.03.009
发表时间: 2019-05-01
影响因子: 8.9
作者:
Verleden, Geert M.;Glanville, Allan R.;Vos, Robin
通讯作者: Vos, Robin